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Abstract
Glioblastoma is the most frequent and aggressive primary brain tumor. The patient can 
be alive with this pathology using the modern standard of intensive combined treatment 
less than 2 years. Between December 2013 and August 2017, 30 patients with newly diag-
nosed supratentorial glioblastoma had received concomitant chemoradiotherapy with 
transcranial radiofrequency hyperthermia. The gross total or the subtotal resection of 
the tumor was made previously in all cases. The median follow-up time after opera-
tion achieved 12 months (95% confidence interval (CI): 8.5–23 months) in this study. 
The median disease-free survival time was 9.6 months (95% CI: 7.2–19.0 months). The 
median overall survival time of patients included in the study was 23.4 months. No 
increase in the systemic side effects of chemotherapy was found compared with the fre-
quency described in the population. Preliminary results had shown that the usage of 
concomitant thermochemoradiotherapy with transcranial radiofrequency hyperthermia 
improves progression-free survival rates. Overall survival rates also tended to increase. 
Given the absence of severe complications, it is necessary to continue research to achieve 
statistically significant results.
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1. Introduction
The median survival time of patients diagnosed with glioblastoma multiforme (GBM) with-
out any treatment is up to 3 months after diagnosis [1]. Modern multimodal treatment includ-
ing surgery and adjuvant chemoradiotherapy with subsequent chemotherapy results in 
longer survival. However, the median survival does not exceed 2 years [2–4]. According to 
population-based studies, the overall 1-, 2-, and 3-year survival rates are approximately 40, 
15, and 7–8%, respectively, and the 5-year survival rates range between 0.05 and 5.5% [1, 5–7].
Glioblastoma multiforme is divided into primary and secondary morphological subtypes. 
Primary GBM accounts for 80–90% of malignant gliomas. They arise de novo and are com-
mon in older adults (mean age 55–62 years). Secondary GBMs represent progression from 
astrocytoma or oligodendroglioma. They manifest in younger adults (mean age 40–45 years) 
and have a lesser degree of necrosis [8–10]. Various genetic disorders characteristic of the pri-
mary and secondary subtypes of glioblastoma have been identified, of which the presence of 
IDH1/2 mutation is the most reliable molecular marker that is determined in all cases of sec-
ondary GBMs, while only about 5% of primary glioblastoma have IDH mutations [1, 11–13]. 
Several studies have shown that IDH1/2 mutations are positive molecular-genetic prognostic 
markers. IDH1/2 mutations make the tumor cells more susceptible to genetic rearrangements 
caused by oxidative stress, thus being a driving force for the development of gliomas. On the 
other hand, tumor cells containing IDH1 mutations become more susceptible to antitumor 
therapy, which confers cytotoxicity through the generation of reactive oxygen species [14]. 
Patients with glioma harboring IDH mutation show a significantly better survival than those 
with an IDH wild-type glioma (24–36 months vs. 9–15 months). The 5-year survival rate 
is nearly zero for patients with primary GBM and up to 80% for patients with secondary 
GBM [12, 15]. In accordance with the updated 2016 edition of the World Health Organization 
(WHO) Classification of Tumors of the Central Nervous System (CNS), glioblastomas are 
classified into glioblastoma, IDH wild-type, glioblastoma, IDH-mutant, and glioblastoma 
NOS. The not-otherwise specified (NOS) is reserved for situations where there is either insuf-
ficient material or the facilities for testing for the specific genotype are not available [16].
Promoter methylation of the gene encoding the DNA repair enzyme O(6)-methylguanine DNA 
methyltransferase (MGMT) is a favorable molecular-genetic prognostic/predictive marker for 
patients with GBM. Approximately 50% of newly diagnosed GBMs have MGMT gene promoter 
methylation. MGMT promoter methylation correlates with a low level of MGMT gene expres-
sion and may be a predictive marker of sensitivity to alkylating agents, resulting in an almost 
twofold increase in the median survival after chemoradiotherapy [8, 17]. In addition, the pres-
ence of mMGMT is associated with an improved survival of GBM patients regardless of the 
treatment strategy and reflects a generally more favorable tumor phenotype [15]. The presence 
of 1p19q co-deletion (loss of heterozygosity on the 1p and 19q chromosome arms) is typical 
for oligodendroglial tumors and indicates a more favorable prognosis. However, in patients 
with glioblastoma, the 1p/19q co-deletion may not be associated with survival benefit [18]. 
The identification of molecular-genetic biomarkers considerably increased our current under-
standing of glioma genesis. However, further studies are required to identify new biomarkers 
to define the clinical and biologic subtypes of glioblastoma [1, 8, 13].
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Multimodal treatment including surgery and adjuvant chemoradiotherapy with subse-
quent chemotherapy is the mainstream treatment modality for GBM. Surgery provides 
material for histological and genetic examinations as well as reduces intracranial pressure 
in most patients with intracranial hypertension. The gross total or the subtotal tumor resec-
tion is an important prognostic factor. Surgery followed by antitumor therapy increases 
survival rates of these patients [19]. However, aggressive surgery within eloquent areas can 
worsen the neurological outcome and performance status of patients, thus decreasing over-
all survival [20, 21]. Moreover, the infiltrative tumor growth beyond the contrast-enhancing 
areas and the presence of tumor cells in the areas of perifocal edema dictate the need for 
further antitumor therapy [22]. Survival of patients treated with surgery alone is less than 
6 months [23].
Adjuvant radiation therapy at the standard total dose of 60 Gy prolonged overall survival to 
10 months. However, tumor recurrence affected about 90% of patients who received radia-
tion therapy [1, 24]. The use of hyperfractionation or dose escalation beyond 60 Gy conferred 
no survival benefit. Dose escalation up to 90 Gy led to a decrease in 1- and 2-year survival 
rates [25, 26]. Attempts to escalate the total dose using brachytherapy and radiosurgery also 
showed no benefit over the standard external beam radiation therapy [27–29].
In the randomized study, concurrent chemoradiation therapy with subsequent adjuvant 
chemotherapy with temozolomide (TMZ) led to an increase in the overall survival of GBM 
patients only up to 14.5 months [30]. The use of anti-angiogenic therapy (bevacizumab) in 
patients with recurrent glioblastomas resulted in survival benefit, with the median overall 
survival rate from 19.6 to 21.5 months [4, 31, 32]. However, two large randomized phase III 
trials showed no improvement in overall survival between patients with newly diagnosed 
GBM receiving and not receiving bevacizumab. The median overall survival of these patients 
did not exceed 17 months [3, 33].
In recent decades, new approaches to GBM treatment including new drugs, and various bio-
logical and physical modifiers have been actively developed. Studies on cell cultures and 
animal models have shown that low intensity and 200 kHz alternating electric fields have 
antitumor activity due to mitotic arrest and apoptosis by disrupting mitotic spindle forma-
tion during metaphase and causing dielectrophoretic movement of polar molecules dur-
ing cytokinesis [34, 35]. In a large prospective randomized phase III trial, tumor-treating 
fields (TTFields) were compared with standard chemotherapy for patients with recurrent 
GBM. The trial indicated that TTFields had an equivalent efficacy when compared with pal-
liative chemotherapy; however, the quality of life was better in the TTFields group [36]. In 
patients who underwent surgery and standard chemoradiotherapy, TTFields administered 
concomitantly with temozolomide significantly improved the median overall survival com-
pared with temozolomide alone (20.5 vs. 15.6 months) [37]. Based on the results obtained, 
TTFields were included in the standard for the treatment of newly diagnosed GBM in the 
United States [38].
Experimental studies have shown that high temperatures can directly induce damage to gli-
oma cells and result in radio- or chemosensitization [39–43]. Unlike healthy tissues, tumors 
have an increased thermal sensitivity, which is caused by biophysical differences between 
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healthy and tumor cells associated with a low efficiency of ATP production in tumor cells. 
Under conditions of ATP deficiency, the active transport of ions through the cell membrane 
is violated and its membrane potential is reduced, thus resulting in higher conductivity and 
dielectric permittivity in cancer tissue than in normal tissue [44, 45].
As recognized in the early 1970s, the main molecular event underlying the biological effects 
of local hyperthermia (LHT) in a clinically significant temperature range (39–45°C) is protein 
damage, including denaturation, exposure to hydrophobic groups, and aggregation with pro-
teins not directly altered by hyperthermia [46–48]. Hyperthermia (temperature above 43°C) 
causes a large number of macromolecular changes that lead to cell death through extensive 
protein denaturation and necrosis. Although significantly fewer macromolecular changes 
occur in the 40.5–42°C range, these changes are still numerous. They occur in different cell 
components and lead to apoptotic cell death [46, 48–50].
Protein aggregation and denaturation have a significant impact within the cell nucleus. 
Changes in nuclear proteins, especially those involved in DNA transcription, replication, and 
repair, cause the inhibition of replication forks and lead to chromosomal aberrations, genomic 
instability, abnormal chromosome segregation, and cell death [46, 47, 49–52]. Cell membranes 
are also extremely sensitive to heat stress due to the complex molecular composition of their 
lipids and proteins. Under the action of LHT, the gel-to-liquid crystal lipid phase transition 
occurs and the proteins lose their structure, thus resulting in an increased permeability of the 
cell membrane. The ion balance (Na+, Mg2+, K+, Ca2+) in cells and in the extracellular environ-
ment is changed, although these changes are not the main mechanism of hyperthermic cell 
death [49, 52].
Ion imbalance results in significant changes in the mitochondrial membrane potential and dis-
turbance of mitochondrial respiration, causing an increase in the activity of oxygen radicals 
and a decrease in the level of oxygen consumption in malignant cells [52, 53]. Depolarization 
of the mitochondrial membrane and the resulting release of oxygen radicals change the oxida-
tion-reduction status of cells and stability of proteins, increasing their sensitivity to LHT. The 
accumulation of lipid peroxidation changes the distribution of Ca2+ and activates the Ca2+-
dependent apoptotic pathway. These effects contribute to the protein-unfolding effects of 
hyperthermia and contribute to effects observed in the nucleus [46, 49].
Irreversible changes in the structure of the protein appear to occur at a temperature of 40°C 
[54–57]. This temperature threshold also temporarily increases the activity of heat shock genes 
that encode heat shock proteins (HSPs). The effect of HSPs may depend on their location: 
intracellularly located HSPs have a protective function, including the correction of misfolded 
protein molecules, the prevention of aggregation, the transport of proteins, and the restriction 
of apoptosis. Intracellularly located Hsp70 can act as a cell survival protein by inhibiting the 
permeability of lysosomal membranes. It also protects tumor cells from monocytic cytotoxic-
ity mediated by tumor necrosis factor [58]. However, HSPs may possess both anti-apoptotic 
(Hsp27, Hsp70, and Hsp90) and proapoptotic effects (Hsp60 and Hsp10) [59, 60]. Finally, 
cell death due to apoptosis can occur through various mechanisms and, perhaps, HSPs can-
not provide protection against all these mechanisms [61]. In contrast to intracellular HSPs, 
membrane-bound and extracellular HSPs may have an immunostimulating effect [50]. Heat 
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has been found to act as the main stimulator of HSP expression and immune stimulation. 
Hyperthermia treatment at 43.5°C enhances cytotoxicity by antibodies monospecific to spe-
cific tumor antigens, suggesting that LHT is capable of enhancing specific immune responses 
against tumor-associated cell membrane antigens [58, 62].
A simplified view that LHT can lead to immune suppression via induction of thermo-tol-
erance in tumor cells has been accepted for many years [52, 58]. It is becoming increasingly 
apparent that in addition to general and limited immune suppression, LHT treatment can lead 
to specific activation of the immune system by inducing certain modifications of the tumor 
cell surface and various forms of cell death. Studies have shown that even local exposure to 
LHT can lead to systemic tumor control by activating the innate immune system [50, 52, 58].
Despite convincing biological justifications, the enthusiasm for the clinical use of LHT as 
monotherapy has decreased due to the fact that heating of human tumors to cytotoxic tem-
peratures between 42 and 45°C is difficult or almost impossible. In living tissues heated for 
more than a few minutes, convective heat losses occur near large blood vessels (diameter of 
~0.5 mm). Such blood vessels act as a heat sink, and one can expect a temperature drop of up 
to 50% [63]. Blood flow provides up to 90% of heat removal. A 10-fold increase in blood flow 
in response to LHT can occur due to the compensatory expansion of arteries and intensive 
perfusion, especially in normal tissues [64–66].
Intratumoral blood flow varies considerably depending on the tumor type. Moreover, even 
within the same tumor, the distribution of the vasculature and blood flow is very heteroge-
neous. Contrary to the general notion that the blood flow in tumors is less than that in normal 
tissues, blood flow in many tumors, especially in small tumors, is actually greater than that 
in the surrounding normal tissues under normal conditions. Typically, the bloodstream of 
the tumor usually decreases as the tumor grows. While studies in small animals suggest 
that LHT induced a decrease in blood flow at 42–43°C, there is evidence that tumors in large 
animals and, more importantly, human tumors, are significantly less sensitive to LHT. In 
general, clinical studies do not suggest a reduction in tumor perfusion at temperatures up 
to 44°C [67].
An increased blood flow can increase tumor growth, as well as the risk of hematogenous metas-
tases, suppressing the possible therapeutic effect of LHT [48, 52, 68]. However, a high blood 
flow can have the opposite effect: a high blood flow provides a more intensive exposure to che-
motherapy and, through increased oxygenation, sensitizes tumor tissue to radiotherapy [69].
A mild temperature (39–42°C), which is not optimal for the induction of direct cell death 
or damage to the vascular system of the tumor, is effective in enhancing tumor response to 
radiation therapy or chemotherapy [70]. Many conditions that contribute to radioresistance, 
including hypoxia, acid medium, and S-phase of the cell cycle, either increase sensitivity to 
LHT or do not change it [50, 52, 70, 71]. LHT-induced increase in tumor perfusion leads to an 
increased tumor tissue oxygenation and an increased tumor radiosensitivity [72].
Under the influence of LHT, both the intrinsic chemical activity of cytostatics and the degree of 
their penetration into cells increase due to the activation of membrane transport, and the direct 
effect of LHT is much higher in hypoxic tissues, in which chemoresistance is observed [47, 71]. 
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The mechanism of enhanced cytotoxicity can include the increase in intracellular accumula-
tion of chemotherapeutic drugs, the inhibition of DNA repair, and S-phase cell cycle block, 
when cells are most sensitive to heat. In addition, LHT increases the production of free radi-
cals and can reverse drug resistance [47, 49, 50].
Based on clinical data demonstrating the synergistic antitumor effect of noninvasive radiofre-
quency hyperthermia used in combination with chemotherapy and radiotherapy for tumors 
from various sites and recurrent glioblastomas, the goal of the study was to evaluate the effec-




Between December 2013 and August 2017, 30 patients with newly diagnosed and histologi-
cally verified supratentorial GBM were included into the study. All patients underwent gross 
total or subtotal microsurgical removal of the tumor. Patients with the evidence of recent 
hemorrhage on baseline magnetic resonance imaging (MRI) of the brain, metal implants, 
and concurrent severe, intercurrent illness were excluded from the study. The study was 
approved by the Ethics Committee of Cancer Research Oncology of Tomsk National Research 
Medical Center. All patients provided informed written consent before being included in the 
study.
2.2. Study design and treatment
This uncontrolled cohort study aimed to assess the tolerability and efficacy of concomitant 
transcranial local radiofrequency hyperthermia combined with radiotherapy and chemo-
therapy with temozolomide to treat newly diagnosed glioblastoma after surgical treatment. 
The IDH mutation status was determined using immunohistochemical staining with the anti-
human IDH1 R132H. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) 
was evaluated using a quantitative methyl-specific polymerase chain reaction in real time. To 
assess surgical outcomes, postoperative contrast-enhanced MRI of the brain was used.
External beam radiation therapy (2.0 Gy per fraction, 5 days per week to a total dose of 60 
Gy) was delivered using Theratron Equinox device. Chemotherapy with temozolomide was 
administered at a dose of 200 mg/m2/day for 5 days for every 28-day cycle. The first course 
of chemotherapy was administered a week after starting radiation therapy. Patients received 
local hyperthermia beginning from the second week of administering external beam radio-
therapy (Figure 1). Local hyperthermia was given two times a week for 60 min. The interval 
between local hyperthermia session and radiation therapy was 20–40 min.
Local hyperthermia was given using Celsius TCS system, which uses electromagnetic 
waves with a frequency of 13.56 MHz (radio waves) for energy transfer. The area of heating 
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exceeded the largest tumor diameter by at least 3 cm and increased proportionally to the 
tumor depth. The heating temperature was gradually increased, focusing on the patient's 
tolerability of the procedure in accordance with the protocol recommended by the device 
manufacturer [73].
The applied energy of the electromagnetic field was increased during seven sessions and 
was dependent on the patients' tolerance. In subsequent treatment sessions, the power did 
not increase. The duration of the treatment session ranged between 20 and 60 min and the 
absorbed power during one session was from 42 to over 324 kJ. To prevent thermal burns 
of the skin and subcutaneous tissue, the surface of the electrodes was cooled by circulating 
deionized water at a temperature of 12–16°C.
2.3. Patient surveillance and follow-up
Baseline contrast-enhanced magnetic resonance imaging (MRI) of the brain was required 
before starting concurrent thermochemoradiotherapy (TCRT). All patients underwent a 
detailed history and physical examination before treatment. Control blood and urine tests 
were performed every week of thermochemoradiotherapy. The neurological and neuro-oph-
thalmic evaluations were performed before and after completion of treatment.
Overall survival and time to tumor progression/recurrence are the most important criteria 
for the assessment of response to adjuvant therapy in patients with GBM. All patients were 
followed up in the outpatient clinic setting. To assess treatment outcomes, contrast-enhanced 
MRI was performed a month after completion of treatment, every 3 months in the first 2 years 
and every 6–12 months thereafter. All MR images were evaluated using Response Assessment 
in Neuro-oncology criteria, RANO [74]. In case of suspicion of tumor progression, an extraor-
dinary MRI was performed. When a patient did not show up for a scheduled appointment, 
information on the patient’s health status was requested in his family relatives.
Adverse effects of radiation therapy were evaluated using RTOG/EORTC Scoring Criteria 
(1995), and side effects of chemotherapy were assessed using the NCIC-CTC grading scale. 
Thermal damage to the skin was classified according to the depth of the lesion.
Figure 1. The protocol for transcranial local radiofrequency hyperthermia combined with radiation therapy and 
chemotherapy with temozolomide.




Progression-free survival and overall survival were assessed using clinical and molecular-
genetic prognostic factors.
Statistical analysis was done using statistical software for Microsoft Office Excel 2010 
(Microsoft Corporation) and Statistica 10.0 (StatSoft).
2.5. Results
Between December 2013 and August 2017, 30 patients with newly diagnosed supratentorial 
glioblastoma were included into the study. Eight patients underwent gross total tumor resec-
tion, and 22 patients underwent subtotal resection. The status of IDH mutation and MGMT 
promoter methylation was analyzed in 73% of patients. Mutation of IDH was found in one 
patient. The frequency of MGMT promoter methylation was 54.5%. There were 19 male and 
11 female patients aged from 21 to 71. The highest frequency of glioblastoma occurred in the 
age range of 50–61 (median age 56 years). Tumor involvement of more than one lobe was the 
most common. Tumors that infiltrated the parietal, temporal, and frontal lobes occurred less 
frequently. The medial structures and the occipital lobe were the least frequent sites in which 
cancer developed (Figure 2).
The median Karnofsky Performance Status (KPS) score was 85% (range 40–90%, 95% CI: 
60–90%) (Figure 3).
The average time from diagnosis to start of radiation therapy was 5.4 weeks. (95% CI: 4.5–6.5 
weeks). Three patients who underwent subtotal tumor resection had disease progression at 
the time of initiation of adjuvant therapy.
Figure 2. GBM location in patients enrolled into the study.
Glioma - Contemporary Diagnostic and Therapeutic Approaches172
2.6. Treatment
Of the 30 patients included into the study, 29 completed concurrent thermochemoradiother-
apy (TCRT). One patient discontinued adjuvant chemotherapy after 42 Gy radiotherapy and 
eight sessions of local hyperthermia because of tumor progression. In this case, disease pro-
gression was diagnosed before starting TCRT. Two patients lost to follow-up after assessing 
immediate response to TCRT.
Patients who completed TCRT continued to receive chemotherapy with temozolomide at a 
dose of 200 mg/m2 per day for five consecutive days in a 28-day cycle. Three patients died 
within 2 months after completion of treatment with no evidence of disease progression. 
Among the patients who died, one patient had extensive destructive pneumonia, one patient 
had severe neutropenia and thrombocytopenia, and another one patient had psycho-organic 
syndrome occurring during atrophy of the brain.
Patients who had disease progression underwent surgery and second-line chemotherapy. 
Repeated radiation therapy at a total dose of 40 Gy was administered to patients who devel-
oped disease progression 1 year after completion of adjuvant radiation therapy.
2.7. Treatment outcomes
Progression-free survival and overall survival were the primary end points in evaluating treat-
ment response in the study. The median follow-up time was 12 months (range 4–51 months; 
95% CI: 8.5–23 months). The median disease-free survival was 9.6 months (95% CI: 7.2–19.0 
months), and recurrence most often occurred within 6–12 months after treatment (Figure 4A). 
Figure 3. Karnofsky performance status score.
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The 1-year disease-free survival rate was 41.3 ± 10.6%. Five patients were followed up for 
more than 24 months. One patient developed recurrent disease 34 months after diagnosis.
During the follow-up period, 11 patients died. Most deaths were registered within 6–12 
months (five patients) and 12–24 months (four patients). The median overall survival time 
was 23.4 months. The 1-year survival rate was 73 ± 8.8%. Four patients had no evidence of 
recurrence 24 months after completion of treatment (Figure 4B).
2.8. Safety and tolerability
Treatment tolerance was assessed by monitoring changes in the functional and neurological 
status of patients and comparing complications from chemotherapy and radiotherapy.
Most patients had no changes in the functional performance status assessed by the Karnofsky 
scale before and after TCRT. In three patients with low KPS score (40%) due to neurological 
deficit, concurrent TCRT led to an increase in KPS score to 60%. One patient had disease pro-
gression during TCRT, and his KPS score decreased from 80 to 40%.
Changes in the KPS status before and after TCRT are shown in Figure 5. An increased func-
tional activity of patients was observed; however, differences were not statistically significant 
(p > 0.05).
The assessment of neurological symptoms before and after TCRT showed no changes in 
neurological deficit in most patients. Neurological symptoms were transient in three cases 
and regressed after vascular therapy in two cases. Worsening of neurological symptoms was 
observed in three patients. One of these patients discontinued radiotherapy at a total dose of 
42 Gy because of disease progression. In two remaining patients, an increase in neurological 
symptoms was not associated with tumor progression and was characterized by the occur-
rence of extrapyramidal symptoms in one case and behavioral disorders in another case. Both 
patients had a history of chronic cerebral ischemia. Regression of focal neurological symptoms 
manifested as a decrease in the severity of pyramidal symptoms was registered after TCRT 
Figure 4. Survival of GBM patients who received concurrent thermochemoradiotherapy. (A) Progression-free survival 
and (B) overall survival.
Glioma - Contemporary Diagnostic and Therapeutic Approaches174
in two patients, and as an improved extremity muscle strength and regression of convulsive 
syndrome in one patient, thus increasing KPS status from 40 to 60%. The patient characteris-
tics with respect to changes in neurological symptoms are shown in Figure 6.
Gastrointestinal toxicity manifested with diarrhea, nausea, or loss of appetite was founded in 
four (13.3%) patients. Grade 3/4 toxicity was not registered. Hepatotoxicity manifested by a 
Figure 5. Functional activity of patients before and after TCRT.
Figure 6. Changes in neurological symptoms after TCRT.
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selective and sustained rise of serum alkaline phosphatase (ALP) activity that was noted in 13 
(43.3%) patients. When the level of serum ALP activity was 2.5 times higher than the normal 
limits, chemotherapy temporarily stopped, and the correction with hepatic protectors was 
performed.
Hematologic toxicity in the form of grade 1/2 leukopenia, grade 1/2 thrombocytopenia, 
and grade 1 anemia was observed in 10 (33.3%) patients. Grade 3/4 leukopenia and throm-
bocytopenia were diagnosed in two (6.7%) patients. Clinical manifestations of grade 3/4 
hematological toxicity were characterized by increased hemorrhage, microhematuria, and 
thrombocytopenic purpura. In one patient, hematoma formation in the tumor bed required 
surgery. There were no cases of febrile neutropenia. In the cases of grade 3/4 hematologic tox-
icity, chemotherapy with a reduced dose of temozolomide continued after achieving absolute 
neutrophil count of >1500 cells/μl and platelet count of >100,000 cells/μl. There were no cases 
of chemotherapy termination because of hematological toxicity.
Grade 1–2 infectious complications after the completion of chemotherapy were revealed in 
three (10%) patients. These complications were manifested by chronic pyelonephritis, bron-
chitis, and oropharyngeal candidiasis and were managed by antibacterial and antifungal 
therapy. Within a month after completion of TCRT, two patients developed severe infections 
(pneumonia), requiring hospitalization and prescription of antibiotic therapy. Both patients 
received dexamethasone at a dose of 16 mg/day intramuscularly.
Acute radiation-induced skin damage was observed in all patients. Allopecia was observed 
in 29 (96.7%) patients, and a second-degree skin radiation reaction was observed in one case 
(3.3%). Complications associated with hyperthermia in the form of thermal injury of skin (up 
to 2 cm in diameter) were diagnosed in three (10%) patients. They did not cause deterioration 
in the physical status of patients. Treatment was conservative, and interruption or cessation of 
treatment was not required. One patient developed inconsistency of a postoperative scar with 
the formation of a cerebrospinal fluid leak. In this case, the excision and suture of the liquor 
fistula were performed, liquorrhea was stopped, and TCRT was successfully completed.
3. Discussion
Several randomized studies showed a significant increase in the overall and disease-free sur-
vival of GBM patients receiving LHT [75, 76]. Seventy-nine patients with newly diagnosed 
glioblastoma were randomized to receive either interstitial high-frequency hyperthermia 
in combination with brachytherapy or interstitial brachytherapy alone. The median time to 
disease progression was longer and the median overall survival was higher in the LHT + 
brachytherapy group than in the group with brachytherapy alone (35 vs. 57 weeks and 76 vs. 
85 weeks, respectively) [75]. Based on the study, interstitial high-frequency hyperthermia for 
GBM treatment was approved by the Food and Drug Administration (FDA). However, the 
invasive nature of LHT limited its use by two procedures to prevent complications associated 
with the installation of antennas and determined the impossibility of combining LHT with 
external beam radiation therapy.
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The effectiveness of magnetic hyperthermia combined with fractionated stereotactic radio-
therapy for recurrent GBM was evaluated in a large two-center study [76]. Patients underwent 
stereotaxic intratumoral injection of a fluid containing magnetic nanoparticles (MNPs), fol-
lowed by heating in an alternating magnetic field. Side effects were moderate, and no serious 
complications were observed. The median overall survival time from the diagnosis was 23.2 
months. Thus, thermotherapy involving the use of alternating magnetic field in conjunction 
with MNPs was proven to be an effective method for treating patients with GBM. However, 
current limitations to the use of magnetic hyperthermia for thermotherapy of GBM patients 
include the high concentration of MNPs required to generate hyperthermia precluding the 
use of MRI, as well as the effective delivery of the MNPs [77].
Modern systems for performing deep LHT allow for noninvasive heating of the tumor. In 
such systems, the electrical parameters of the circuit are automatically measured and individ-
ually adjusted to ensure control and high efficiency of the procedure. Temperature monitor-
ing in tumor tissue is provided by calculation based on the measurement of absorbed energy 
and tissue impedance [66, 68].
There are a number of disadvantages of LHT: the excessive heating of subcutaneous fat, insta-
bility in a radiofrequency field and its dependence on the size of electrodes, their location, 
distance between them, and on the dielectric parameters of tissues, as well as the ease of the 
formation of the “hot spots,” that is, the maximum electrical field in places with a high dielec-
tric contrast [64, 78, 79].
There are published data indicating that the conductivity of the cerebrospinal fluid is at least 
four to six times higher than that of the gray and white matter. Thus, it is reliable to predict the 
presence of “hot spots” along the gray matter-cerebrospinal fluid (CSF) boundary, as well as 
along white matter-CSF boundary. Moreover, the induced electric field distribution is highly 
nonuniform. The electric field direction plays a significant role: the internal and near-surface 
electric field is higher in a tissue with low conductivity and lower in a tissue with high con-
ductivity. As a result of tissue heterogeneity, the electric field in the brain does not decrease 
smoothly with distance from the transducers, as it would in a homogeneous tissue. In addi-
tion, electric field “hot spots” can occur far from the arrays, giving rise to a complex spatial 
distribution [80, 81].
This nonuniformity of the electric field determines high safety requirements for LHT, as it 
has a number of negative effects on neuronal structures and functions, causing disturbances 
in electrochemical depolarization, transmembrane ion transport, and destruction of cellular 
signaling mechanisms and mitochondrial functions. Despite the fact that irreversible changes 
in the protein structure occur at temperatures above 40°C [55, 56], this temperature thresh-
old also activates heat shock proteins to increase thermal tolerance and enhance cell protec-
tion [82]. Since irreversible changes in normal nerve tissue are detected after hyperthermia at 
42–42.5°C for 40–60 min [56, 57], the brain temperature should not exceed 42°C.
The attempts to use noninvasive magnetic resonance thermometry during transcranial radiofre-
quency LHT were unsuccessful, because it was impossible to combine an electromagnetic LHT 
device with an MRI system. Invasive thermometry for LHT is time-consuming, uncomfortable, 
Concurrent Thermochemoradiotherapy in Glioblastoma Treatment: Preliminary Results
http://dx.doi.org/10.5772/intechopen.76264
177
and risky for the patient. Considering these data, we conducted a study simulating radiofre-
quency deep LHT using a realistic bioequivalent phantom. Results of thermometry showed 
that the temperature in the normal brain substance and cerebrospinal fluid did not exceed 
the physiologic parameters. The rise in the tumor temperature enhanced the efficacy of radio-
therapy [83].
Several clinical studies on transcranial radiofrequency hyperthermia for relapsed malignant 
brain tumors showed a low frequency of objective response (from 7 to 25% of cases) and the 
median overall survival time of 6–9 months after the onset of hyperthermia [84–86]. It was 
difficult to determine the effectiveness of treatment, since there were no data on the overall 
survival from the time of surgical treatment.
A preliminary analysis of the results of this uncontrolled cohort clinical trial showed that at 
a median follow-up of 12 months, the median progression-free survival was 9.6 months in 
patients who received TCRT (CI 95%: 7.2–19.0 months). These results were better than those 
described in the randomized study conducted by Stupp [30], who reported that the median 
disease-free survival time was 6.9 months (95% CI: 5.8–8.2 months) and 7.1 months (95% CI: 
5.9–8.2 months) in GBM patients treated with Stupp regimen and tumor-treating fields, respec-
tively [30, 37]. The median overall survival time of patients included in the study was 23.4 
months. However, the result was not statistically significant because the median follow-up was 
up of 12 months.
Given a small number of patients included in the study, the evaluation of molecular-genetic 
prediction factors (IDH mutations and MGMT methylation) was important to avoid errors 
associated with a disproportionate number of patients with a favorable prognosis. The molec-
ular-genetic features of tumors in patients enrolled in the study could not be the cause of 
improved survival. However, the study demonstrated a high frequency of subtotal tumor 
resections, which was a negative predictor factor [1].
Since radiofrequency hyperthermia was administered locally, an increase in the systemic side 
effects of chemotherapy compared with the frequency described in the population was not 
determined. The appearance of neurologic toxicity during chemotherapy with temozolomide 
not described in the previous studies [30] was more likely to be associated with an increase in 
edema and ischemic disorders. This was confirmed by the fact that neurological toxicity was 
mainly observed during the second course of chemotherapy, when external beam radiation 
dose accumulated. However, none of the patients had evidence of ischemic stroke.
Concurrent hyperthermia and chemoradiotherapy did not result in an increased frequency of 
local injuries associated with transcranial local radiofrequency hyperthermia [79]. However, 
it is necessary to pay attention to the fact that during TCRT, one patient developed a fistula 
in the area of a postoperative scar, which indicated an impairment of reparative processes.
4. Conclusion
Preliminary results of the analysis of 30 patients with supratentorial newly diagnosed glioblas-
toma who received adjuvant thermochemoradiotherapy using transcranial radiofrequency 
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hyperthermia showed an increase in progression-free survival rates. Overall survival rates 
also tended to increase. Given the absence of severe complications, it is necessary to continue 
research to achieve statistically significant results.
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